Edesa Biotech prices $25 million public offering
Canada-based Edesa Biotech (Nasdaq: EDSA) has priced an underwritten public offering expected to generate approximately $25 million in gross proceeds. The company’s shares slumped 17.2% to $4.76 following the announcement.
The offering includes 3,870,500 common shares and up to 675,000 pre-funded warrants, each paired with warrants to purchase additional shares at $7.50 per share. The combined price is $5.50 per common share plus warrant. Guggenheim Securities is the sole book-running manager, with a 30-day option for underwriters to purchase up to 681,825 additional shares and warrants. The offering is expected to close around August 21, 2026.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze